TABLE 1.

Contemporary Trials: Preoperative/Perioperative Therapy in Locally Advanced Gastroesophageal Junction Cancer

Trial (Reference)	Treatment	No. of Patients	GEJ, %	Complete Resection Rate, %	Pathologic No Status, %	Pathologic Complete Response Rate, %	Survival		Local Failure, %
							Median, mo	Overall, %
MAGIC (Cunningham 20065)a	Peri-op ECF + surgery	250	11.2	69	31	0	24	5-y, 36	14
	Surgery	253	11.9	66	27	NA	20	5-y, 23	21
STO3 (Cunningham 201723)a	Peri-op ECX + Bev + surgery	530	51	61b	NR	11	NR	3-y, 48	NR
	Peri-op ECX + surgery	533	50	64	NR	8	NR	3-y, 50	NR
OEO5 (Alderson 201711)	Pre-op ECX (×4) + surgery	446	67	66	39	7	26.1	3-y, 42	10
	Pre-op 5FU/Cis (×2) + surgery	451	67	59	30	1	23.4	3-y, 39	13
FLOT4-AIO (Al-Batran 201712)a	Peri-op FLOT + surgery	356	56	84	49	16c	50	3-y, 57	NR
	Peri-op ECF/ECX + surgery	360	56	77	41	6c	35	3-y, 48	NR
CROSS (Shapiro 2015,7 van Hagen 201213)d	Pre-op CRT with Carbo/paclitaxel + surgery	178	22	92	69	29	49	5-y, 47	22
	Surgery	188	26	69	26	N/A	24	5-y, 33	38
POET (Stahl 2009,21 201722)	Pre-op 5FU/Cis → Pre-op CRT with Cis/Etop + surgery	60	100	72	64	16	31	5-y, 40	21
	Pre-op 5FU/Cis + surgery	59	100	70	37	2	21	5-y, 24	38

Abbreviations: 5FU, 5-fluorouracil; Bev, bevacizumab; Carbo, carboplatin; Cis, cisplatin; pre-op CRT, preoperative chemoradiation. ECF, epirubicin, cisplatin, 5FU; ECX, epirubicin, cisplatin, capecitabine; Etop, etoposide; FLOT, 5-fluorouracil, oxaliplatin, docetaxel; GEJ, gastroesophageal junction; NA, not applicable; NR, not reported; Pre-op, preoperative; peri-op, peri-operative.

^aThe study included gastric and esophageal/GEJ cancers.

^bThe rate varied by tumor location (69% of patients with esophageal/GEJ cancers vs 87% of those with gastric cancers achieved R0).

^cResults from the phase II trial.

^dThe study included adenocarcinoma and squamous cell carcinoma.

Numbers in bold indicate statistically significant values.